24:
820:
645:
307:
are highly reliable and conserve the allergic agents in their best state of allergy. In
September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.
824:
649:
950:
293:), and pediatric allergies for which there are currently no effective treatments. It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.
480:
730:
299:
The clinical development program for
Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the
262:
The founders provided initial startup capital. Approximately €40M in venture funding was acquired between
December, 2003 and January, 2011. In March 2012, an initial public offering on the
360:
296:
The
Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.
1201:
788:
1186:
738:
1196:
426:
763:
646:"Successful Initial Public Offering (IPO) for DBV Technologies on the NYSE Euronext regulated market in Paris. DBV Technologies raises € 40.5 million"
623:
528:"DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults"
1206:
370:
875:
1181:
734:
506:
731:"DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children"
575:
798:
995:
236:
671:
252:
821:"DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut's Phase IIb Clinical Trial in Peanut Allergy"
1005:
853:
848:
701:
868:
502:
702:"Sofinnova Partners' portfolio company DBV Technologies successfully raises €40.5M in its oversubscribed IPO"
527:
216:
139:
96:
452:"Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy (VIPES)"
1191:
365:
427:"DBV Technologies and Centre d'Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement"
259:) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).
550:
1176:
861:
793:
905:
455:
46:
1045:
1085:
960:
925:
212:
1130:
1050:
248:
64:
1095:
579:
399:
1155:
945:
335:
282:
60:
247:
DBV Technologies was founded in 2002 by Doctor Pierre-Henri
Benhamou (specializing in
23:
1170:
1110:
940:
935:
675:
263:
86:
72:
54:
273:
and Pascal
Wotling is Chief Technical Operations Officer and Chief Quality Officer.
1120:
970:
235:. Viaskin Peanut clinical development has received Fast Track designation from the
451:
303:, which is used to determine allergies of children. The ready-to-use standardised
223:. DBV Technologies is known for developing "Viaskin" technology for administering
679:
1145:
1100:
1080:
930:
900:
885:
601:
304:
76:
32:
1140:
1135:
1060:
1055:
705:
224:
1035:
1015:
990:
985:
331:
228:
1125:
1105:
980:
955:
1150:
1115:
1075:
1070:
1040:
1020:
975:
920:
915:
624:"DBV Technologies secures $ 25.5 million in Series C financing round"
290:
220:
145:
100:
68:
1090:
1065:
1030:
1025:
1010:
910:
256:
232:
195:
1000:
672:"NYSE Euronext welcomes DBV Technologies to its European market"
286:
857:
270:
172:
162:
361:"Paris Is Europe Health IPO Hub With Most Sales in 20 Years"
481:"DBV Seeks Immunotherapeutic to Desensitize Food Allergies"
648:. Lundbeckfond Ventures. March 28, 2012. Archived from
190:
182:
152:
134:
115:
92:
82:
52:
42:
30:
231:to intact skin while avoiding any transfer to the
602:"DBV Technologies closes $ 25.5m financing round"
869:
8:
16:
1202:Biotechnology companies established in 2002
876:
862:
854:
251:), the engineer Bertrand Dupont (from the
15:
503:"Pierre-Henri Benhamou, DBV Technologies"
316:
1187:Medical technology companies of France
789:"Skin patch could cure peanut allergy"
725:
723:
570:
568:
168:Kevin Trapp (Chief Commercial Officer)
758:
756:
394:
392:
390:
388:
354:
352:
186:Allergy treatments, Allergy diagnosis
7:
764:"Division of Allergy and Immunology"
446:
444:
421:
419:
417:
359:Albertina Torsoli (March 28, 2012).
326:
324:
322:
320:
823:. 22 September 2014. Archived from
737:. November 14, 2012. Archived from
735:Biotechnology Industry Organization
507:Global Intellectual Property Center
474:
472:
1197:Companies listed on Euronext Paris
578:. DBV Technologies. Archived from
14:
530:. Evaluate Pharma. August 2, 2012
479:Marie Powers (January 16, 2013).
266:exchange yielded €40.5M (Euros).
678:. March 29, 2012. Archived from
429:. FierceBiotech. 17 October 2012
22:
626:. News Medical. January 5, 2011
281:DBV Technologies is focused on
237:US Food and Drug Administration
797:. May 30, 2011. Archived from
604:. MTB Europe. February 7, 2011
1:
1207:2002 establishments in France
769:. Chicago Childrens Research
211:is a publicly owned French
1223:
1182:Companies based in Bagneux
249:Pediatric Gastroenterology
896:
253:Arts et MĂ©tiers ParisTech
21:
890:(as of 5 November 2021)
551:"Peanut Allergy Patch"
366:Bloomberg Businessweek
215:firm headquartered in
332:"DBV Technologies SA"
888:companies of France
77:CAC Mid 60 Component
794:The Daily Telegraph
209:DBV Technologies SA
18:
17:DBV Technologies SA
901:AĂ©roports de Paris
827:on 29 October 2014
402:. DBV Technologies
1164:
1163:
961:Dassault Aviation
891:
741:on April 14, 2013
582:on March 17, 2013
373:on March 31, 2012
213:biopharmaceutical
206:
205:
198:.dbv-technologies
125:Christophe Dupont
1214:
1131:Technip Energies
1051:Maisons du Monde
966:DBV Technologies
889:
878:
871:
864:
855:
849:Official Website
837:
836:
834:
832:
817:
811:
810:
808:
806:
785:
779:
778:
776:
774:
768:
760:
751:
750:
748:
746:
727:
718:
717:
715:
713:
708:. March 29, 2012
698:
692:
691:
689:
687:
668:
662:
661:
659:
657:
652:on March 4, 2016
642:
636:
635:
633:
631:
620:
614:
613:
611:
609:
598:
592:
591:
589:
587:
572:
563:
562:
560:
558:
553:. Beyond Allergy
546:
540:
539:
537:
535:
524:
518:
517:
515:
513:
499:
493:
492:
490:
488:
476:
467:
466:
464:
462:
448:
439:
438:
436:
434:
423:
412:
411:
409:
407:
396:
383:
382:
380:
378:
369:. Archived from
356:
347:
346:
344:
342:
328:
269:Daniel Tassé is
202:
199:
197:
110:
108:
38:DBV Technologies
26:
19:
1222:
1221:
1217:
1216:
1215:
1213:
1212:
1211:
1167:
1166:
1165:
1160:
936:Casino Guichard
892:
882:
845:
840:
830:
828:
819:
818:
814:
804:
802:
801:on June 1, 2011
787:
786:
782:
772:
770:
766:
762:
761:
754:
744:
742:
729:
728:
721:
711:
709:
700:
699:
695:
685:
683:
682:on June 7, 2012
670:
669:
665:
655:
653:
644:
643:
639:
629:
627:
622:
621:
617:
607:
605:
600:
599:
595:
585:
583:
574:
573:
566:
556:
554:
548:
547:
543:
533:
531:
526:
525:
521:
511:
509:
501:
500:
496:
486:
484:
478:
477:
470:
460:
458:
450:
449:
442:
432:
430:
425:
424:
415:
405:
403:
398:
397:
386:
376:
374:
358:
357:
350:
340:
338:
330:
329:
318:
314:
279:
245:
194:
178:
171:Ramzi Benamar (
155:
148:
142:
130:
122:Bertrand Dupont
106:
104:
75:
67:
57:
47:Société Anonyme
35:
12:
11:
5:
1220:
1218:
1210:
1209:
1204:
1199:
1194:
1189:
1184:
1179:
1169:
1168:
1162:
1161:
1159:
1158:
1153:
1148:
1143:
1138:
1133:
1128:
1123:
1118:
1113:
1108:
1103:
1098:
1093:
1088:
1086:RĂ©my Cointreau
1083:
1078:
1073:
1068:
1063:
1058:
1053:
1048:
1043:
1038:
1033:
1028:
1023:
1018:
1013:
1008:
1003:
998:
993:
988:
983:
978:
973:
968:
963:
958:
953:
948:
946:CNP Assurances
943:
938:
933:
928:
923:
918:
913:
908:
906:Air France–KLM
903:
897:
894:
893:
883:
881:
880:
873:
866:
858:
852:
851:
844:
843:External links
841:
839:
838:
812:
780:
752:
719:
693:
663:
637:
615:
593:
564:
549:Heather Legg.
541:
519:
494:
468:
456:ClinicalTrials
440:
413:
400:"Presentation"
384:
348:
315:
313:
310:
283:food allergies
278:
275:
244:
241:
204:
203:
192:
188:
187:
184:
180:
179:
177:
176:
169:
166:
161:Daniel Tasse (
158:
156:
153:
150:
149:
144:
138:
136:
132:
131:
129:
128:
126:
123:
119:
117:
113:
112:
94:
90:
89:
84:
80:
79:
61:Euronext Paris
58:
53:
50:
49:
44:
40:
39:
36:
31:
28:
27:
13:
10:
9:
6:
4:
3:
2:
1219:
1208:
1205:
1203:
1200:
1198:
1195:
1193:
1192:French brands
1190:
1188:
1185:
1183:
1180:
1178:
1175:
1174:
1172:
1157:
1154:
1152:
1149:
1147:
1144:
1142:
1139:
1137:
1134:
1132:
1129:
1127:
1124:
1122:
1119:
1117:
1114:
1112:
1109:
1107:
1104:
1102:
1099:
1097:
1094:
1092:
1089:
1087:
1084:
1082:
1079:
1077:
1074:
1072:
1069:
1067:
1064:
1062:
1059:
1057:
1054:
1052:
1049:
1047:
1044:
1042:
1039:
1037:
1034:
1032:
1029:
1027:
1024:
1022:
1019:
1017:
1014:
1012:
1009:
1007:
1004:
1002:
999:
997:
994:
992:
989:
987:
984:
982:
979:
977:
974:
972:
969:
967:
964:
962:
959:
957:
954:
952:
949:
947:
944:
942:
939:
937:
934:
932:
929:
927:
924:
922:
919:
917:
914:
912:
909:
907:
904:
902:
899:
898:
895:
887:
879:
874:
872:
867:
865:
860:
859:
856:
850:
847:
846:
842:
826:
822:
816:
813:
800:
796:
795:
790:
784:
781:
765:
759:
757:
753:
740:
736:
732:
726:
724:
720:
707:
703:
697:
694:
681:
677:
676:NYSE Euronext
673:
667:
664:
651:
647:
641:
638:
625:
619:
616:
603:
597:
594:
581:
577:
571:
569:
565:
552:
545:
542:
529:
523:
520:
508:
504:
498:
495:
482:
475:
473:
469:
457:
453:
447:
445:
441:
428:
422:
420:
418:
414:
401:
395:
393:
391:
389:
385:
372:
368:
367:
362:
355:
353:
349:
337:
333:
327:
325:
323:
321:
317:
311:
309:
306:
302:
297:
294:
292:
288:
284:
276:
274:
272:
267:
265:
264:NYSE Euronext
260:
258:
254:
250:
242:
240:
238:
234:
230:
226:
222:
218:
214:
210:
201:
193:
189:
185:
181:
174:
170:
167:
164:
160:
159:
157:
151:
147:
141:
137:
133:
127:
124:
121:
120:
118:
114:
102:
98:
95:
91:
88:
87:Biotechnology
85:
81:
78:
74:
70:
66:
62:
59:
56:
51:
48:
45:
41:
37:
34:
29:
25:
20:
1121:Sopra Steria
1061:MĂ©tropole TV
971:Derichebourg
965:
829:. Retrieved
825:the original
815:
803:. Retrieved
799:the original
792:
783:
771:. Retrieved
743:. Retrieved
739:the original
710:. Retrieved
696:
684:. Retrieved
680:the original
666:
654:. Retrieved
650:the original
640:
628:. Retrieved
618:
606:. Retrieved
596:
584:. Retrieved
580:the original
576:"Management"
555:. Retrieved
544:
532:. Retrieved
522:
510:. Retrieved
497:
485:. Retrieved
459:. Retrieved
431:. Retrieved
404:. Retrieved
375:. Retrieved
371:the original
364:
339:. Retrieved
300:
298:
295:
280:
268:
261:
246:
208:
207:
135:Headquarters
43:Company type
805:February 8,
773:February 8,
745:February 8,
712:February 8,
686:February 8,
656:February 8,
630:February 8,
608:February 8,
586:February 8,
557:February 8,
534:February 8,
512:February 8,
487:February 8,
461:February 8,
433:February 8,
406:February 8,
377:February 8,
341:February 8,
305:patch tests
1177:CAC Mid 60
1171:Categories
1081:OPmobility
1001:Fnac Darty
886:CAC Mid 60
831:28 October
483:. BioWorld
312:References
154:Key people
33:Trade name
1141:Vallourec
1056:Mercialys
1046:Lagardère
884:Selected
706:Sofinnova
336:Bloomberg
225:allergens
55:Traded as
1036:JCDecaux
991:Eutelsat
986:Europcar
229:antigens
183:Products
83:Industry
1146:Valneva
981:Eurazeo
956:Covivio
931:Bolloré
301:E-patch
277:Product
243:History
217:Bagneux
191:Website
140:Bagneux
116:Founder
105: (
97:Bagneux
93:Founded
71::
63::
1156:Wendel
1151:Virbac
1116:Soitec
1101:S.E.B.
1076:Nexity
1071:Nexans
1041:Korian
1021:Imerys
976:Eramet
951:Coface
921:Aperam
916:Amundi
291:peanut
221:France
146:France
101:France
69:Nasdaq
1096:Rubis
1091:Rexel
1066:Neoen
1031:Ipsos
1026:Ipsen
1016:Iliad
1011:Icade
911:ALTEN
767:(PDF)
257:Paris
233:blood
103:(2002
1126:SPIE
1106:SCOR
833:2014
807:2013
775:2013
747:2013
714:2013
688:2013
658:2013
632:2013
610:2013
588:2013
559:2013
536:2013
514:2013
489:2013
463:2013
435:2013
408:2013
379:2013
343:2013
289:and
287:milk
200:.com
107:2002
73:DBVT
1136:TF1
1111:SES
1006:GTT
996:FDJ
941:CGG
926:Bic
271:CEO
255:in
227:or
196:www
173:CFO
163:CEO
65:DBV
1173::
791:.
755:^
733:.
722:^
704:.
674:.
567:^
505:.
471:^
454:.
443:^
416:^
387:^
363:.
351:^
334:.
319:^
239:.
219:,
143:,
99:,
877:e
870:t
863:v
835:.
809:.
777:.
749:.
716:.
690:.
660:.
634:.
612:.
590:.
561:.
538:.
516:.
491:.
465:.
437:.
410:.
381:.
345:.
285:(
175:)
165:)
111:)
109:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
